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hazard function were run to estimate time to thresholds
of vision loss. The resulting hazards were used to inform
transition probabilities in a Markov model, to estimate
effects (discounted at 3%) for an average patient. RE-
SULTS: The estimate of vision years gained was 0.57
during the trial, and 0.82 at 5 years. Benefits decreased
with age and baseline visual acuity. CONCLUSION:
Based on one year data, the majority of benefit was esti-
mated to accrue within the trial time frame, and benefits
differ across subgroups. Treatment costs may be offset by
delaying costs of blindness.
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A key purpose in conducting pharmacoeconomic (PE)
and health outcomes (HO) research is to aid in the deci-
sion-making process. However, surprisingly few studies
within the literature have evaluated the relevance of this
information to decision-makers. OBJECTIVES: The pur-
pose of this study was to evaluate the relevance of PE and
HO information to health plan decision-makers in man-
aging the pharmacy benefit. METHODS: A qualitative
research method using telephone interviews on a conve-
nience sample of managed care and PBM decision-mak-
ers was used. Participants were presented with 16 hypo-
thetical statements incorporating key PE and HO concepts
and asked to judge the relevance of the statements. Re-
spondents were also prompted to provide a rationale for
their judgement. Questions relating to respondent’s train-
ing and familiarity with PE concepts were also included.
RESULTS: Over 80% of respondents (n  16) were
pharmacists, with one-third working for PBMs. State-
ments related to quality-of-life, cost-of-prevention, cost/
year of life saved, increased life expectancy, and 2-year
savings were relevant to 80% of respondents. Willing-
ness to pay (WTP), cost to society and global cost of ill-
ness statements were considered irrelevant by 35%. Re-
sponse trends to the above indicate that copays preclude
the relevance of WTP information; societal perspectives
are generally not relevant to benefit management, and
plan demographics are more relevant than global demo-
graphics. Statements related to PE modeling were rele-
vant provided that inputs and assumptions were perti-
nent to the user. Statements reported in terms of quality
adjusted life year were difficult for respondents to con-
ceptualize. CONCLUSIONS: These findings suggest that
some PE and HO information is more relevant than oth-
ers in the management of the pharmacy benefit.
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The pharmaceutical industry (PI) is a principal provider
of pharmacoeconomic (PE) data to health care organiza-
tions (HCOs). Therefore, assessing how this information
is perceived and used by HCOs from the PI perspective
can provide insights for future development of PE infor-
mation. OBJECTIVES: The purpose of this study was to
describe the PI perceptions regarding the use of PE infor-
mation by HCOs. METHODS: A structured phone inter-
view was conducted with PI personnel who routinely in-
teract with HCOs, including account managers, scientific
liaisons, and PE/outcomes research managers. Partici-
pants were asked to comment with regard to the fre-
quency of use and importance of various types of PE in-
formation that is provided to HCOs. RESULTS: A total
of 21 subjects were interviewed. About 95% stated that
the PE information provided to HCOs in the previous
year was helpful. The majority of respondents (76%)
stated PE information was considered by HCOs for most
or some decisions. There was significant variation when
asked whether PE articles were relevant, credible, and un-
derstandable to HCOs. Reprints of PE data and HCO-
specific information were most commonly listed as best-
received by HCOs. A majority (81%) also felt there were
barriers to using PE information in HCOs; “isolated fo-
cus on the pharmacy budget” was listed as the most com-
mon barrier. Only one-third of respondents felt their
company met the PE needs of HCOs. The remainder
listed lack of PE information as the primary cause for not
meeting the PE needs of HCOs. CONCLUSION: While
respondents felt that PE information is commonly used
and is perceived as valuable, this study has identified po-
tential limitations to the currently available information.
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Much emphasis is currently being placed on determining
the proper methodology for conducting economic analy-
ses of pharmaceuticals. However, perhaps equally impor-
tant is the need for consideration of how this information
is actually being used by decision-makers. The most re-
cent examination of this issue occurred in 1996. OBJEC-
TIVES: The purpose of this study was to increase our un-
derstanding of how pharmacoeconomic information is
used by decision-makers in managed care and to identify
perceived strengths and weaknesses of the available in-
formation given the current state of the pharmacy bene-
